Debiopharm International SA
Lausanne, VD
- UEI
- YN12U3HMB8W7
- CAGE
- SCGE0
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Other
- SAM.gov registration date
- Physical address
- Chem. Messidor 5/7, 1006 Lausanne, Switzerland
- Website
- debiopharm.com
- Founded
- 1979
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | $1,945,029 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Aimmax Therapeutics Inc. | Durham, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| 3 Point Bio LLC | Boxford, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Curza Inc. | Salt Lake City, UT | — |
| Basilea Pharmaceutica International Ltd, Allschwil | Allschwil, BL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Venatorx Pharmaceuticals Inc. | Chadds Ford, PA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Debiopharm International SA is a Swiss biopharmaceutical company that provides drug development services to the U.S. government through federal contracts and grants. Specifically, Debiopharm develops novel antibiotics targeting drug-resistant bacteria.
Through a federal subcontract, Debiopharm is developing antibiotics against Neisseria gonorrhoeae, the causative agent of gonorrhea. This work involves synthesizing drug compounds and carrying out preclinical studies to select a development candidate drug. The prime contractor is Trustees of Boston University.
Additionally, Debiopharm has received multiple federal subgrants to develop antibiotics against Acinetobacter baumannii and Neisseria gonorrhoeae. These grants support medicinal chemistry optimization, efficacy studies in animal models, pharmacokinetic profiling, and toxicology studies to identify preclinical drug candidates. The prime grantees have been Trustees of Boston University. The grants are awarded under programs for developing therapeutics to address antibiotic resistance.
In summary, Debiopharm provides specialized drug discovery and development services to create new antibiotics targeting urgent and serious drug-resistant bacteria. The company performs this work under federal contracts and grants, by partnering with academic institutions leading prime awards in this space.
Quick answers
Is Debiopharm International SA registered in SAM.gov?
Yes. Debiopharm International SA's SAM.gov registration is active through March 13, 2027.
On GovTribe
See Debiopharm International SA's full federal record
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors